Akebia Therapeutics (AKBA)
(Delayed Data from NSDQ)
$1.31 USD
-0.06 (-4.38%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $1.31 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.31 USD
-0.06 (-4.38%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $1.31 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth C Momentum A VGM
Zacks News
Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Entera Bio Ltd. (ENTX) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.
Here's Why You Should Consider Buying Akebia (AKBA) Stock
by Zacks Equity Research
Here, we discuss some reasons why buying Akebia (AKBA) stock now may turn out to be a prudent move.
Zacks Industry Outlook Highlights Corcept, Amneal, Bioventus, Foghorn and Akebia
by Zacks Equity Research
Corcept, Amneal, Bioventus, Foghorn and Akebia have been highlighted in this Industry Outlook article.
5 Small Drug Stocks to Buy as Innovation Reaches Peak
by Kinjel Shah
Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, BVS, FHTX, and AKBA may prove to be good additions to one's portfolio.
Are Medical Stocks Lagging Acrivon Therapeutics, Inc. (ACRV) This Year?
by Zacks Equity Research
Here is how Acrivon Therapeutics, Inc. (ACRV) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.
Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 33.33% and 4.30%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 0% and 20.72%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD
by Zacks Equity Research
Akebia (AKBA) gains during premarket hours on Mar 28 as its key product Vafseo (vadadustat) tablets receive FDA's approval for the treatment of anemia due to chronic kidney disease.
Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q4
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 100% and 1%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Rigel Pharmaceuticals (RIGL) Reports Break-Even Earnings for Q4
by Zacks Equity Research
Rigel (RIGL) delivered earnings and revenue surprises of 100% and 0.26%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Akebia Therapeutics (AKBA) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -100% and 4.61%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
MediWound (MDWD) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
MediWound (MDWD) delivered earnings and revenue surprises of 124.39% and 14%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Xenetic Biosciences (XBIO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xenetic Biosciences (XBIO) delivered earnings and revenue surprises of 38.94% and 47.96%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of 25% and 11.71%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Are Medical Stocks Lagging InMode (INMD) This Year?
by Zacks Equity Research
Here is how InMode (INMD) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.
KalVista (KALV) Surges 15% on Update From Angioedema Study
by Zacks Equity Research
KalVista (KALV) announces a positive update from its late-stage study on its lead product candidate, sebetralstat, in the treatment of hereditary angioedema attacks. The stock rises 15% in response.
Journey Medical (DERM) to Post Skin Disease Data, Stock Rises 26%
by Zacks Equity Research
Journey Medical (DERM) rises 26% on Monday after announcing the tentative date for reporting top-line results from its late-stage studies evaluating DFD-29 in treating papulopustular rosacea.
Avalo (AVTX) Fails to Meet Goal in Asthma Study, Stock Down 89%
by Zacks Equity Research
Avalo (AVTX) announces that it failed to meet the primary endpoint in its mid-stage poorly controlled non-eosinophilic asthma study. The stock falls 89% on Monday following the news.
Catalyst (CPRX) to Gain DMD Drug Licensing Rights From Santhera
by Zacks Equity Research
Catalyst (CPRX) announces entering into a definitive agreement to acquire licensing rights in North America to Santhera's DMD treatment candidate, vamorolone, which is currently under FDA review.
Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Akebia Therapeutics (AKBA) and Haemonetics (HAE) have performed compared to their sector so far this year.
Baudax (BXRX) Up on New Neuromuscular Blocking Agent Study Data
by Zacks Equity Research
New data from Baudax's (BXRX) study on BX1000 confirms greater comparability of the highest dose of the candidate to the standard dose of rocuronium as a neuromuscular blockade. Stock gains 4%.
All You Need to Know About Akebia Therapeutics (AKBA) Rating Upgrade to Buy
by Zacks Equity Research
Akebia Therapeutics (AKBA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are Medical Stocks Lagging Akebia Therapeutics (AKBA) This Year?
by Zacks Equity Research
Here is how Akebia Therapeutics (AKBA) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.
Is Novartis (NVS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Novartis (NVS) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.